We are hiring! We are seeking a highly motivated and experienced Strategy & Operations Manager to join our AI team and drive the management and execution of internal and external projects while contributing to research efforts and supporting strategic decision-making. The candidate will play a key role in supporting execution of key strategic partnerships as well as shaping our platform and business development strategy. Click here to learn more and apply: https://lnkd.in/enGcD46m #PangeaBio #Jobs #Startup #AI #DrugDiscovery #Biotech #Entrepreneurship
About us
Pangea develops transformative medicines for neurological disorders, deploying AI to uncover promising molecules from natural sources with prior evidence of efficacy and tolerability in humans based on traditional use.
- Website
-
pangeabio.com
External link for Pangea Bio
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- London
- Type
- Privately Held
- Founded
- 2021
Locations
-
Primary
London, GB
Employees at Pangea Bio
Updates
-
Our Co-founder and Executive Director R&D Thomas Pfeiffer will present our work with OT-003, a potential novel small-molecule therapeutic targeting cognitive and negative symptoms associated with Schizophrenia at #ACNP2024 in Phoenix today. Please get in touch if you would like to meet or just visit Thomas at our poster. #Schizophrenia #biotech #drugdevelopment #PangeaBio #Neuropsychiatry #Neuroplasticity
Day 1 for Pangea Bio at #ACNP2024 in Phoenix almost under the belt! Today has been a great mix of thought-stimulating symposia and presentations of recent clinical results. Looking forward to the next three days and to hearing about the frontiers of drug discovery and development to tackle neuropsychiatric diseases. Also, I can't wait to discuss our lead compound OT-003's potential for treating Schizophrenia, and spread the word about Pangea's vision and mission. Get in touch if you wish to meet and visit us at our poster on Tuesday. #Schizophrenia #biotech #drugdevelopment #pangeabio #neuropsychiatry #neuroplasticity https://lnkd.in/eux9wKNt
-
Our CITO, Professor Andreas Bender, will give a presentation on Artificial Intelligence in Drug Discovery at the pharmaceutical conference, CPHI, in Riyadh, Saudi Arabia, on 11 December 2024. This talk coincides with the expansion plans of Pangea Bio into the MENA region and our aims to build both research and business links in Saudia Arabia, the UAE, and beyond. Get in touch at [email protected] if you are also attending and would like to meet. For more information please see https://lnkd.in/g67VB2fW #PangeaBio #Startup #DrugDevelopment #DrugDiscovery #AI #Biotech #Innovation
-
Starting today, we will be attending #ACNP2024, the Annual American College of Neuropsychiatry Meeting, in Phoenix, Arizona US, from 8-11th December. This is a fantastic opportunity to engage with leaders, collaborators and investors in the field and discuss the latest progress in neuropsychiatric research and drug development. We can’t wait for the meeting to get started. If you’re attending and would like to connect with our Co-founder and Executive Director R&D Thomas Pfeiffer, please don’t hesitate to reach out or go and see him directly. Thomas will present our work with OT-003, a potential novel small-molecule therapeutic targeting cognitive and negative symptoms associated with Schizophrenia on Tuesday. #ACNP2024 #PangeaBio #DrugDevelopment #Schizophrenia #BrainHealth #Neuropsychiatry #Neuroplasticity
-
🚀 Exciting news from The Economist: in their recent article "AI will boost drug development in 2025," they feature our CITO, Andreas Bender, and his insightful take on how AI is revolutionizing drug development. Andreas highlights that by reducing failures in phase-two clinical trials by just 20%, the pharmaceutical industry could save nearly $450 million per drug in development costs. This is a game-changer that not only boosts efficiency but also reduces risks and accelerates the delivery of life-saving therapies. 💡 At Pangea Bio, we’re tackling the challenge to improve clinical efficiency early on. Our proprietary discovery platform empowers us to select therapeutically relevant species from medicinal plants, decode their chemical profiles, and predict potential biological activity in the human body. This scalable discovery engine can move from plant to hit compound in a fraction of the time and cost of conventional methods and improve outcomes for patients worldwide faster. 🌍 Read the full article here: https://lnkd.in/ew7VFASU #PangeaBio #Innovation #DrugDevelopment #Pharma #Technology #HealthTech #ClinicalEfficiency #Economist #CITO #Research #AI #FutureOfHealthcare
AI will boost drug development in 2025
economist.com
-
This week, our colleague Daniel Crusius represented our team at Metabomeeting 2024 in Liverpool, hosted by the University of Liverpool and the Metabolic Profiling Forum (MPF). Daniel had the opportunity to present some of our latest work on metabolomics foundation models during the Bioinformatics and Statistical Approaches session on Wednesday morning. 🧪📊 It was a fantastic experience to engage with so many brilliant minds in the field of metabolomics, exchanging insights and pushing the boundaries of what we can achieve with advanced computational techniques. Daniel's presentation sparked some great discussions, and we're thrilled to be contributing to the ongoing advancements in metabolomics research. A big thank you to the University of Liverpool and MPF for hosting such a dynamic and insightful event! 💡 #PangeaBio #Startup #MetaboMeeting24 #Metabolomics #Bioinformatics #StatisticalApproaches #ResearchInnovation #Biotech #DrugDevelopment #SmallMolecules
-
Big congratulations to our co-founder and Kadence Bio CEO John Boghossian for winning the Start-up Spotlight Competition with our affiliate company Kadence Bio at #BIOEurope2024 in Stockholm earlier this month! What an amazing achievement! 👏 🙌 https://lnkd.in/eDa4Xu-g
John Boghossian, our CEO, recently attended #BIOEurope 2024 in Stockholm, a flagship life sciences partnering conference that brings together global innovators and investors to connect and advance the industry. At this year's event, John had the opportunity to pitch Kadence Bio as part of the Start-up Spotlight Competition, and we are proud to announce that Kadence Bio won! Winning this competition provides the opportunity to partner with Bayer through their Bayer Co.Lab program, gaining access to world-class expertise and their ecosystem facilities. This recognition is a testament to our vision and progress in developing the first FDA-approved treatment for premature ejaculation, aiming to address a major unmet need in men's health. We’re looking forward to kicking off the Co.Lab program later this month as well as continuing conversations with potential partners as we push ahead with our mission to improve sexual and mental wellbeing. #BioEurope2024 #KadenceBio #MensHealth #Biotech #StartupSpotlight #Winner
-
🌍 It was an exciting week for our team at the Medical Biotechnology Summit 2024 in Riyadh, where our co-founders, Lars Christian Wilde and John Boghossian, connected with industry leaders, investors, and partners. It’s inspiring to witness the emerging biotech ecosystem in Saudi Arabia, with a clear focus on innovation, sustainability, and global collaboration. We’re thrilled to be part of the conversation and look forward to exploring opportunities to drive breakthroughs in biotechnology and contribute to Vision 2030 priorities. #PangeaBio #Startup #Biotech #Innovation #AI #MedicalBiotechnologySummit #SaudiArabia #Networking #FutureOfHealthcare
-
We are hiring! We are looking for a Lead Computational Chemist/Molecular Modeller at Pangea Bio, in either #Berlin or #London, hybrid mode. Click here to learn more and apply: https://lnkd.in/eAxWuFSr #PangeaBio #Startup #Biotech #AI #DrugDiscovery #ComputationalChemistry #DrugDevelopment
-
Our colleague Dr. Fabien Schultz will be attending the 23rd International Congress of the International Society for Ethnopharmacology and the 2nd International Congress of the African Phytomedicine Scientific Society (ISE-APSS2024), hosted by the University of Pretoria from October 23-26, 2024, at the Cape Town International Convention Centre, South Africa! This is a fantastic opportunity to engage with experts in the field, share insights, and explore the latest developments in ethnopharmacology and phytomedicine. If you’re also attending and would like to connect with Fabien, feel free to reach out at [email protected] Learn more about the conference: https://lnkd.in/eD--eJcj #Ethnopharmacology #Networking #PangeaBio #DrugDevelopment #DrugDiscovery #NaturalProducts #ISEAPSS2024 #CapeTown #SouthAfrica
23rd International Congress of The International Society for Ethnopharmacology & the 2nd International Congress of the African Phytomedicine Scientific Society (ISE-APSS2024) - International Society for Ethnopharmacology
https://ethnopharmacology.org